Selective IL-2 responsiveness of regulatory T Cells through multiple intrinsic mechanisms supports the use of low-dose IL-2 therapy in type 1 diabetes

A. Yu, I. Snowhite, F. Vendrame, M. Rosenzwajg, D. Klatzman, A. Pugliese, T. R. Malek

Research output: Contribution to journalComment/debatepeer-review

Original languageEnglish (US)
Pages (from-to)S73
JournalDiabetes Technology and Therapeutics
StatePublished - Feb 2016

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology
  • Medical Laboratory Technology

Cite this